Published: 11 October 2017

Committees

Comments on Agenda Items for the 59th meeting of the Medicines Classification Committee to be held on Tuesday 7 November 2017

A total of 15 submissions commenting on agenda items for the 59th meeting were received (PDF Document, 3,079 KB, 56 pages). Some submissions comment on more than one agenda item.

Twelve comments were received regarding the proposed reclassification of codeine from pharmacy-only and restricted medicines to a more restricted classification (agenda item 5.3).

Two comments were received regarding the principles of harmonisation (agenda item 5.4).

One comment was received regarding the proposed reclassification of hydrocortisone 1% w/w from prescription medicine to restricted medicine when combined with aciclovir 5% w/w in primary packs of not more than 2 g for dermal use in adults or children 12 years of age and older for the treatment of herpes labialis (cold sores) (agenda item 6.1).

One comment was received regarding the proposed reclassification of penciclovir from pharmacy-only medicine to general sale medicine when for external use for the treatment of herpes labialis (agenda item 6.2).

One comment was received regarding the proposed classification of Patent Blue V as a prescription medicine (agenda item 7.1).

Three comments were received regarding the proposed classification of Meningococcal Group B Vaccine as a prescription medicine (agenda item 8.1.8).

One comment was received regarding the proposed reclassification of cetirizine from pharmacy-only medicine to general sale medicine when in preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over, when in a maximum pack size of 10 days’ supply labelled with a recommended daily dose not exceeding 10 mg of cetirizine hydrochloride (agenda item 8.2.1a)